Royal Caribbean ( RCL 0.78%) is set to launch a river cruise business through its upscale Celebrity brand, and demand has ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Shares of luxury cruise operator Viking (NYSE:VIK) jumped 4.8% in the afternoon session after positive results from rival ...

Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and ...

Both companies may succeed in this industry.

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking could ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, ...

JP Morgan analyst Matthew Boss reiterated an Overweight rating on the shares of Viking Holdings Ltd (NYSE:VIK) and raised the price target to $58 from $50. From 2017 to 2019, VIK’s pre-pandemic annual ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $29.06, moving -3.9% from the previous trading session. This change lagged the S&P 500's daily loss of 0.43%. Meanwhile, the Dow ...